Literature DB >> 1312171

Inhibition of protein phosphorylation by opioid-inhibited adenylyl cyclase in rat brain membranes.

L M Fleming1, G Ponjee, S R Childers.   

Abstract

Opioid inhibition of adenylyl cyclase is a major second messenger system associated with opioid receptors in brain. To identify membrane phosphoproteins whose phosphorylation state is modulated by opioid inhibition of adenylyl cyclase, rat striatal membranes were preincubated with opioid agonists in the presence of 500 microM 5'-adenylyl-imidodiphosphate (which acted as a substrate for adenylyl cyclase, but not for protein kinase) before addition of [gamma-32P]ATP. Under these conditions, adenylyl cyclase in the membranes formed cyclic AMP, which stimulated cyclic AMP-dependent protein kinase. This process was confirmed by observing forskolin-stimulated phosphorylation of two bands of MW 85 and 63 kDa, which were also stimulated directly by cyclic AMP. Forskolin-stimulated phosphorylation of these two bands was inhibited by 15 to 30% by opioid agonists such as D-Ala2-Met5-enkephalinamide. This inhibition of phosphorylation was mediated by opioid receptors, because it required both sodium and GTP, and was blocked by naloxone. These results suggest that these two proteins may be primary targets of opioid-inhibited adenylyl cyclase in striatal membranes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312171

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene.

Authors:  Z Rahman; S J Gold; M N Potenza; C W Cowan; Y G Ni; W He; T G Wensel; E J Nestler
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

Review 2.  The Mechanisms Involved in Morphine Addiction: An Overview.

Authors:  Joanna Listos; Małgorzata Łupina; Sylwia Talarek; Antonina Mazur; Jolanta Orzelska-Górka; Jolanta Kotlińska
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.